Navigation Links
Venaxis' APPY1 Test Passes Futility Analysis in Pivotal Clinical Study

CASTLE ROCK, Colo., July 15, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced that the external Data and Safety Monitoring Board (DSMB) created as part of the Company's pivotal clinical trial for the APPY1 Test has recommended continuation of the pivotal clinical trial, based upon completion of the first of two futility analyses included in the clinical trial design.  Venaxis will host a conference call and webcast tomorrow morning, July 16, 2013, at 8:30 a.m. ET, to discuss the DSMB's recommendation and to provide a general corporate update.

The futility analysis, which consisted of an independent review of the validity, integrity, and clinical and scientific relevance of the ongoing study, was performed on the first 579 patients to complete the study.  The study will enroll a total of 2,000 evaluable patients.  The next and final futility analysis will include data from the first approximately 1,200 patients.

Steve Lundy, President and CEO of Venaxis, stated, "While the results of the study remain blinded to Venaxis, we are very pleased that the pivotal clinical trial has passed this important interim analysis step successfully.  The APPY1 Test performed very well in the previous 500-patient study, so we regard this outcome as encouraging and we look forward to the next assessment.  Enrollment in the pivotal study continues to accelerate as our recently initiated sites ramp-up their enrollment.  We expect to complete enrollment for the pivotal study by the end of 2013, and if the results are positive, file for FDA clearance in the first quarter 2014.  In the meantime, we continue to execute on our commercial milestones in Europe, where we are preparing to initiate economic outcomes studies at leading hospitals.  Importantly, with our recent financing, we have sufficient capital to achieve major regulatory and commercial milestones.  While we remain prudent with the use of cash, we see no financial obstacles to reaching these significant value inflection points."

Venaxis strengthened its financial position with an additional $14.4 million in gross proceeds from a May public offering led by Piper Jaffray & Company.  The Company currently estimates cash, cash equivalents, and short-term investments to be approximately $20 million at the close of the second quarter 2013, which will be reflected in the Company's Form 10-Q to be filed in the coming weeks.  

Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, stated, "We remain on track for a full-scale European launch for the APPY1 Test beginning in the fourth quarter of this year.  We currently have four market development agreements in place and we are in the final process of selecting partners in additional target countries, including Germany, the UK, and France.  In terms of our existing partner agreements, we are initiating and expect to complete several outcome studies by the end of the third quarter 2013 and anticipate leveraging robust data from those studies to demonstrate objectively the clinical and economic value of using the APPY1 Test in the hospital emergency room. We remain focused on laying a solid foundation as we continue onto full-scale commercialization of APPY1 in Europe and advance to commercialization in the United States."

Conference Call Information
The Company has scheduled its quarterly conference call and webcast for tomorrow, July 16, 2013, at 8:30 a.m. ET.  Interested participants and investors may access the conference call by dialing 1-800-860-2442 (U.S.), 1-866-605-3852 (Canada) or 1-412-858-4600 (international).  A live audio webcast will be accessible via the Investor Relations section of the Venaxis web site,  

A telephonic replay of the call will be available for 30 days beginning at 10:30 a.m. ET on July 16, 2013.  Access numbers for this replay are 1-877-344-7529 (U.S./Canada) and 1-412-317-0088 (international); conference ID: 10031489.  The webcast replay will remain available in the Investors Relations section of the Venaxis web site for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Prospectus filed on May 24, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD; (212) 375-2664
Claire Sojda; (212) 375-2686

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Venaxis Announces Pricing of Offering of Common Stock and Warrants
2. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
3. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
4. Eastern Clinical Trials Russia CRO Passes EMA Inspection
5. Legendary Author And Screenwriter Nora Ephron Passes Away At 71; Solar Cigarette Pays Tribute To Such A Rare Talent
6. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
7. Free Expo-Hall Passes for ATA 2012
8. Accuray Surpasses 600 Installations Globally
9. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
10. New Approaches in Immunogenicity Assessment Using the New SQiDlite™ System: Case Study Analysis, New Life Science Webinar Hosted by Xtalks
11. Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032
Post Your Comments:
(Date:10/9/2015)... ... October 09, 2015 , ... ... current methods of separating those cells from their surroundings for research, diagnostics, and ... cells. , To address this, Ann Arbor-based startup Akadeum Life Sciences ...
(Date:10/8/2015)...  Sorrento Therapeutics, Inc. (NASDAQ:  SRNE; Sorrento), a ... and associated pain, announced today that Dr. Henry Ji, President ... the Aegis Capital Corporation 2015 Growth Conference in ... 2015 Growth ConferenceDate:Friday, October 9, 2015Time:10:00 to 10:30 ... Wynn in Las Vegas, NV , ...
(Date:10/8/2015)... , Oct. 8, 2015 Celemics, a ... expansion into the North American market with the establishment ... and Europe , has ... of Target Enrichment methodology and sample preparation for DNA ... facilitates both hereditary and somatic genetic testing more accurately, ...
(Date:10/8/2015)... Del. , Oct. 8, 2015  Today, ... CRISPR-Cas technologies for genome editing, jointly announced a ... and Caribou have cross-licensed their respective patent portfolios, with ... technology applications in major row crops, and non-exclusive ... --> --> ...
Breaking Biology Technology:
... Aug. 5 TriMix Laboratories LLC today,announced it ... Solutions,as the exclusive pharmacy for prescription fulfillment of ... as a first line and secondary,treatment for erectile ... compounding pharmacy which makes TriMix gel(TM) medicine for,each ...
... Makes Strategic Investment in CogState Ltd. to Support Partnership, ... global implementation of cognitive testing ... Key points:, -- United BioSource Corporation (UBC) ... the use of cognitive testing in,clinical trials., -- ...
... Inc. (IVT), a,vaccine development company, today announced receipt ... its vaccine platform. The specific,patent, Vaccines with enhanced ... exclusivity that an effective, long-term immune,response to treat ... comprising of,an antigen, an adjuvant, vesicles known as ...
Cached Biology Technology:
(Date:9/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that the ... Modern, will feature the Wocket® smart wallet for the ... Touch Of Modern is an online ... to its 7.2 million members. Customers are affluent, urban ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunication and ... and assets. Keys, identity badges, and numeric keypads are ... with the structure of palm and fingers of an ... palm. Hand geometry scanners with infrared light and reflectors ...
(Date:8/31/2015)... August 31, 2015 Growing need ... in government digitization projects to drive India ... published TechSci Research report, " India Biometrics Market Forecast & ... is projected to grow at a CAGR of over ... anticipated on account of extensive use of biometric technology in ...
Breaking Biology News(10 mins):
... a ,safe, tan based on ultraviolet (UV) radiation, according to ... Pigment Cell & Melanoma Research , the official journal ... the Society for Melanoma Research. The authors of the ... cell biology, dermatology and epidemiology have examined the effects ...
... engines in Song-Charng Kong,s Iowa State University laboratory have ... two-stroke internal combustion engine in 1879. There are ... horsepower, better efficiency, cleaner burning and greater reliability. ... graduate students and all kinds of sensors recording engine ...
... Someday, your car might have the metallic finish of ... wing, and the reflectors might be patterned on the ... researchers who have developed a method to rapidly and ... fraction of mutations in evolutionary processes are successful," says ...
Cached Biology News:
... is a completely redesigned and updated version ... accepts the full line of well-proven Alpha ... in thermal performance as the DNA Engine ... easy transport of protocols among platforms. ...
... Pierce ready-to-use 2-D gel marker mix was designed ... gel marker mix contains a complement of seven ... of value to those who use markers to ... molecular weight values of proteins undergoing 2-D separation ...
... DNA Engine Tetrad thermal cycler expands ... pioneering PTC-200 DNA Engine cycler. ... capacity with a footprint only twice ... for laboratories that run massive quantities ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
Biology Products: